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Relative to protein content, the activity of glucose-6-phosphate d hydrogenase and 6-phosphogluconate de- 
hydrogenase and the rate of glucose metabolism by the pentose cycle pathway in tumoral insulin-producing 
cells were similar to or higher than those found in normal rat islets. Hence, the decreased secretory response 
of tumoral cells to glucose is apparently not attributable to any major anomaly in glucose handling by the 
hexose monophosphate pathway. 
Tumoral insulin-producing cell 
1. INTRODUCTION 
At variance with normal pancreatic B-cells, 
tumoral insulin-producing cells of the RINmSF cell 
line display a poor secretory response to glucose 
[l-3]. Our aims were to measure in tumoral cells 
the metabolism of glucose in the pentose cycle and 
glycolytic pathway, and to compare the results 
with those obtained in pancreatic islets exposed to 
either a low (5.6 mM) or high (16.7 mM) concen- 
tration of glucose. 
2. MATERIALS AND METHODS 
Pancreatic islets were isolated by the collagenase 
method from fed albino rats [4]. Tumoral insulin- 
producing cells were cultured, harvested and 
counted as described [5]. 
For measuring the activity of glucose-6-phos- 
phate dehydrogenase and 6-phosphogluconate de- 
hydrogenase, the tumoral cells were sonicated (3 
times 5 s) in Tris-HCI buffer (50 mM, pH 8.0) con- 
taining MgClz (5 mM), EDTA (1 mM), KC1 
(100 mM), cysteine (2 mM) and bovine albumin 
(0.1 mg/ml). The enzymatic activity was measured 
spectrophotometrically at 22°C in the same buffer 
and in the presence of glucose 6-phosphate (2 mM) 
or 6-phosphogluconate (2 mM) and NADP (0.5 
mM). The reaction velocity was stable over at least 
Pancreatic islet Pentose cycle 
10 min and proportional to the number of cells 
(0.2-l .O x lo6 cells/cuvette) with a variation coef- 
ficient close to 3.6%. The results are expressed as 
pmol NADPH formed/min per lo3 cells. In con- 
trol experiments, we have verified that, under the 
present experimental conditions, purified enzymes 
yielded full enzymic activities and that the mea- 
surement of glucose-6-phosphate dehydrogenase 
activity was little affected by the activity of en- 
dogenous 6-phosphogluconate dehydrogenase. 
The methods used to measure the production of 
3Hz0 from D-[5-3H]glucose [6] and oxidation of 
D-[l-‘4C]glucose or D-[6-‘4C]glucose [7] were 
identical to those described previously, except that 
all experiments were conducted in a Krebs phos- 
phate buffer [8] equilibrated against ambient air. 
The protein content of islet cells was measured as 
in [9]. 
Mean values ( f SE) are expressed together with 
the number of individual observations (n). The 
fraction of glucose metabolism that occurs by the 
pentose cycle was calculated according to Katz and 
Wood [lo]. 
3. RESULTS 
In RINmSF cells, the activity of glucosed-phos- 
phate dehydrogenase and 6-phosphogluconate de- 
hydrogenase averaged 4.10 + 0.15 (n = 14) and 
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Table 1 
Metabolism of glucose in tumoral and normal islet cells 
RINmSF cells 
2.8 mM D-glucose 
(pmol/60 min per lo-’ cells) 
Pancreatic islets 
5.6 mM D-glucose 16.7 mM D-glucose 
(pmol/60 min per islet) 
D-[5-3H]Glucose utilization 
114.65 k 4.66 (30) 
D-[1-‘“C]Glucose utilization 
3.43 -t 0.19 (50) 
D-[6-‘“C]Glucose oxidation 
1.89 f 0.10 (50) 
43.28 k 1.91 (34) 119.48 k 8.17 (10) 
4.01 k 0.29 (20) 11.17 +- 0.76 (20) 
2.20 k 0.12 (20) 9.18 k 0.50 (20) 
0.414 + 0.043 (n = 4) pmol/min per lo3 cells, re- 
spectively. 
The rate of D-[5-3H]glucose utilization in 
tumoral cells incubated at 2.8 mM D-glucose 
largely exceeded that found in pancreatic islets in- 
cubated at 16.7 mM D-glucose. Indeed, if allow- 
ance is made for the fact that the protein content 
averages 139 f 13 ng/103 tumoral cells and 745 + 
88 ng/islet, the rate of D-[5-3H]glucose conversion 
to 3Hz0 amounted to 825 + 34 and 160 + 11 
pmol/60 min per pg protein in tumoral cells in- 
cubated at 2.8 mM glucose and pancreatic islets in- 
cubated at 16.7 mM glucose, respectively. 
In tumoral cells, the rate of D-[6-‘“Clglucose ox- 
idation only represented 1.6% of that of D- 
[5-3H]glucose utilization, whereas such a ratio 
averaged 5.1 and 7.7% in pancreatic islets in- 
cubated at 5.6 and 16.7 mM D-glucose, respective- 
ly. However, if expressed relative to the protein 
content, the rate of D-[6-‘4C]glucose oxidation was 
similar in tumoral cells incubated at 2.8 mM D- 
glucose (13.6 f 0.7 pmol/60 min per fig protein) 
and pancreatic islets incubated at 16.7 mM D- 
glucose (12.3 + 0.7 pmol/60 min per ,ug protein), 
respectively. 
The oxidation of D-[ 1-‘“Clglucose exceeded that 
of D-[6-‘4C]glucose, even in pancreatic islets in- 
cubated at high glucose concentration (P < 0.025 
by paired comparison). From these data we have 
calculated both the fraction of the total metabol- 
ism of glucose that occurs by the pentose cycle and 
the absolute flow rate through this pathway. The 
fraction of glucose metabolism occurring by the 
cycle averaged 0.46% in tumoral cells incubated at 
2.8 mM D-glucose and 1.51% and 0.61% in pan- 
2 
creatic islets incubated at 5.6 and 16.7 mM D- 
glucose, respectively. The flow rate through the 
cycle averaged 1.58 pmol/60 min per IO3 tumoral 
cells and 1.96-2.18 pmol/60 min per islet (at 
5.6-16.7 mM D-glucose). Relative to protein con- 
tent, these values amounted to 11.36 and 
2.64-2.93 pmol/60 min per pg protein in tumoral 
cells and pancreatic islets, respectively. These data 
indicate that the relative contribution of the pen- 
tose cycle to the total generation of triose phos- 
phates was lower in tumoral than normal islet cells 
whilst, in absolute terms, the flow rate through 
the cycle was higher in the tumoral cells than in 
pancreatic islets. 
4. DISCUSSION 
In pancreatic islets, glucose-6-phosphate dehy- 
drogenase and 6-phosphogluconate dehydrogenase 
activities range from 5.1-27.0 and 3.2-9.2 pmol/ 
min per yg protein [9,11,12], respectively, as com- 
pared to 29.4 and 3.0 pmol/min per pg protein in 
the tumoral insulin-producing cells. In both cell 
types, the rate of glucose metabolism through the 
pentose cycle pathway is much lower, averaging no 
more than 0.19 pmol/min per fig protein in 
tumoral cells incubated at 2.8 mM D-glucose and 
0.04-0.05 pmol/min per pg protein in pancreatic 
islets incubated at 5.6-16.7 mM glucose. Thus, in 
terms of either enzymatic activity in cell homog- 
enates or flow rate in intact cells, the tumoral cells 
are equally or better equipped than normal islet 
cells for the handling of glucose 6-phosphate in the 
hexose monophosphate pathway. This finding sug- 
gests that the poor secretory responsiveness of 
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tumoral cells to glucose is not attributable to any 
obvious anomaly in the metabolism of glucose in 
the pentose cycle pathway. Incidentally, the pre- 
sent results confirm that the flow through such a 
cycle is not increased, in normal pancreatic islets, 
when the glucose concentration is raised from 2.8 
to 16.7 mM [ 11,131. These observations and the re- 
cent demonstration that the metabolism of glucose 
in the pentose cycle is ,!I-stereospecific in intact 
islets [14] also suggest that the generation of 
NADPH in the cycle is not responsible for the 
stimulant action of glucose upon insulin release. 
When expressed relative to the overall rate of 
glucose utilization, the oxidation of both D- 
[ l-‘4C]giucose and D-[6-‘4C]glucose was much 
lower in tumoral cells than pancreatic islets. 
However, when expressed relative to protein con- 
tent, the mitochondrial oxidation of D-[6-‘4C]glu- 
case was virtually identical in tumoral cells ex- 
posed to 2.8 mM D-glucose and pancreatic islets 
exposed to a much higher concentration of glucose 
(16.7 mM). In both cell types, these glucose con- 
centrations are known to evoke a close-to-maximal 
increase in glycolytic flux 114,151. Hence, the 
similarity in oxidation rate could suggest hat the 
poor secretory responsiveness to glucose of the 
tumoral cells is not attributable to a defect in mito- 
chondrial oxidation. 
As judged from the present data, the major 
anomaly in the metabolism of glucose in tumoral 
cells consists of a much higher rate of glycolysis. 
We have recently indicated that this coincides with 
an abnormally low ratio for lactic/pyruvic acid 
output from these tumoral cells [14]. It is con- 
ceivable, therefore, that the poor secretory re- 
sponse to glucose of tumoral cells is attributable to 
an abnormal cytosolic redox state rather than any 
quantitative defect in the absolute flow rate 
through either the pentose cycle, glycolytic 
pathway or Krebs cycle. 
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